迪苏尔菲拉姆通过向MD-2来阻止炎症TLR4信号传递
Yang Bai1,2, Rui Min1,2, Pengcheng Chen1
1The Center for Microbes, Development and Health, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
概括
迪苏尔菲拉姆 (DSF) 是一种酒药物,通过向MD-2来抑制托尔类受体4 (TLR4) 信号传递. 这阻断了炎症和神经炎症,显示了治疗帕金森病的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 由脂聚糖 (LPS) 激活的托尔类受体4 (TLR4) 激活会触发对宿主防御至关重要的强烈炎症反应,但涉及到诸如败血症等病理.
- 现有的TLR4抑制剂未能证明临床有效性,需要新的治疗策略.
- 由TLR4信号驱动的神经炎症,有助于帕金森病 (PD) 中的多巴胺能神经元损失.
研究的目的:
- 为了确定TLR4介导的炎症信号传递的新型抑制剂.
- 在炎症和神经退行症的临床前模型中研究dissulfiram (DSF) 的治疗潜力.
主要方法:
- 迪苏尔菲拉姆 (DSF) 被评估为其抑制TLR4-MD-2复合体形成和信号传递的能力.
- 在体外评估了DSF对巨细胞炎症媒介产生的影响.
- 用N-甲基-4--1,2,3,6-四胺 (MPTP) 的小鼠模型来研究DSF对神经炎症和多巴胺基神经元存活的影响.
主要成果:
- 迪苏尔菲拉姆 (DSF) 通过对MD-2蛋白的Cys133进行共价性修改,特别抑制TLR4信号传递.
- 在巨细胞中,DSF有效地阻断了LPS诱导的炎症性细胞因子,化学因子和干扰素的产生.
- 在帕金森病的MPTP小鼠模型中,DSF显著降低了神经炎症,保护了多巴胺基神经元,并改善了运动功能.
结论:
- 迪苏尔菲拉姆 (DSF) 是TLR4-MD-2炎症信号传递的强有力的抑制剂.
- 在帕金森病模型中,DSF显示了神经炎症和神经保护的治疗潜力.
- 用DSF等药物向MD-2可能为治疗炎症性疾病 (包括PD) 提供一个可行的策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
174
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
261
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
261


